logo-loader

Botanix Pharmaceuticals’ shares ride higher following successful acne study

Published: 13:40 29 Jan 2018 AEDT

1517194290_shutterstock_586967087
Better results compared to other FDA approved products

Botanix Pharmaceuticals Ltd’s (ASX:BOT) shares are trading circa 31% higher intra-day at $0.17 after successfully completing a phase 1b study in patients with acne, which met all the designated endpoints.

The phase 1b acne patient study was designed to evaluate the safety, tolerability and pharmacology of the company’s lead product for acne, BTX 150.

Botanix’s study was conducted at four of the leading acne investigative sites in Australia and enrolled 21 subjects with moderate to severe acne, with 18 subjects completing the study.

Subjects were treated for 28 days and then assessed for safety, tolerability, and efficacy at day 28 and at a follow-up visit on day 35.

Better results compared to other FDA approved topical acne products

Top line data indicated that BTX 1503 is effective at reducing the number of inflammatory and non-inflammatory acne lesions after 4 weeks of treatment.

On average, inflammatory lesions decreased by circa 47% by day 28 of the study.

This significant reduction is greater than any other FDA approved topical acne product, for which data is available after 4 weeks of treatment.

The study results also demonstrated that BTX 1503 was safe and well tolerated in the study. There were no serious adverse events and no subjects discontinued the study due to an adverse event.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 20 minutes ago